Kempharm (ZVRA): יחס מחיר להכנסות

The orphan drug status of Zevra Therapeutics (ZVRA) creates a powerful regulatory barrier against generics, as confirmed by the price-to-sales ratio chart on GURU.Markets, where 3.60 expresses the metric's current value. Growth is driven by the success of Miplyffa and the expansion of the neurological portfolio, while final margins are based on FDA approvals, insurance coverage, and royalties from Azstarys.

For Zevra Therapeutics (ZVRA), which monetizes innovations in rare disease therapy through government payments, business scale is determined by the sales volume of specialized drugs. The ratio of market value to revenue, reflected through the company's smoothed P/S, allows investors to assess the premium for future growth, separating the fundamental value of operations from speculative market noise to protect capital.